Kisspeptin-10

Background

Kisspeptin‑10 (KP‑10) is a decapeptide (10–amino‑acid) fragment derived from the C‑terminus of the KISS1 gene product, originally identified as a metastasis‑suppressor factor in melanoma and other cancers.[11] KISS1 gives rise to a family of RF‑amide peptides (kisspeptins), of which KP‑10 represents the minimal sequence required for high‑affinity receptor activation and full biological activity.[11][12]

KISS1 and its receptor KISS1R (also known as GPR54) were subsequently recognized as critical regulators of hypothalamic control of puberty and fertility via stimulation of gonadotropin‑releasing hormone (GnRH) neurons.[12] KP‑10 has therefore been widely used as a pharmacological tool to probe kisspeptin signaling in reproductive neuroendocrinology, oncology, and other systems. Despite extensive preclinical investigation and some early‑phase human work with kisspeptin analogues, KP‑10 itself is not an approved therapeutic in the United States or European Union.[12]

In addition to its role in reproduction and cancer biology, KP‑10 has been explored in models of osteoarthritis, gestational diabetes, toxic injury, and as a scaffold for imaging or radionuclide therapy, reflecting broad interest in kisspeptin pathways as therapeutic targets.[2][3][5][13]

Mechanism of action

Receptor targets

KP‑10 is an agonist of the KISS1 receptor (KISS1R/GPR54), a rhodopsin‑like G protein‑coupled receptor expressed in the hypothalamus, pituitary, gonads, vasculature, placenta, and various tumors.[11][12] KP‑10 binds with high affinity to KISS1R and activates predominantly Gq/11‑coupled signaling.

Intracellular signaling

Upon KP‑10 binding, KISS1R activation triggers:

• Phospholipase C (PLC) activation, inositol trisphosphate (IP3) production, and intracellular Ca²⁺ mobilization, leading to depolarization of GnRH neurons and increased GnRH release.[12]
• Activation of downstream ERK1/2 and p38 MAPK pathways, which contribute to effects on cell proliferation, migration, and apoptosis in several cell types.[11]
• Regulation of cytoskeletal dynamics via FAK (focal adhesion kinase) and Rho family GTPases, mechanisms implicated in anti‑metastatic and anti‑angiogenic activity.[11]

Physiological and pathophysiological roles

• Reproductive axis: KP‑10 potently stimulates GnRH secretion, which in turn increases luteinizing hormone (LH) and follicle‑stimulating hormone (FSH) release from the pituitary, coordinating pubertal onset and gonadal function.[12]
• Cancer metastasis and angiogenesis: KP‑10 derived from KISS1 can inhibit tumor cell migration and invasion and suppress tumor angiogenesis by down‑regulating VEGF expression and inhibiting FAK/Rho‑dependent signaling.[11]
• Metabolic and other actions: KISS1R expression has been reported in pancreatic islets, adipose tissue, and cartilage; KP‑10 has been shown to modulate insulin signaling, inflammatory responses, and cellular senescence in preclinical models.[2][5][12]

Evidence summary

Tumor angiogenesis and metastasis

A key mechanistic study by Cho et al. (2012) investigated KP‑10 in endothelial and tumor models.[11]

• Design: In vitro assays using human umbilical vein endothelial cells (HUVECs) and in vivo Matrigel plug neovascularization models in mice.[11]
• Sample size: HUVEC experiments typically used triplicate or quadruplicate wells per condition; mouse groups comprised 6–8 animals (as reported in methods).[11]
• Findings: KP‑10 inhibited endothelial cell proliferation, migration, and tube formation, reduced VEGF expression via suppression of Sp1 transcriptional activity, and attenuated FAK and Rho GTPase activation.[11]
• Outcome: In vivo, KP‑10 significantly reduced angiogenesis in Matrigel plugs and suppressed tumor vascularization, supporting an anti‑angiogenic and anti‑metastatic role.[11]

A more recent radiopharmaceutical development study synthesized DOTA‑KP‑10 for gallium‑68 and lutetium‑177 labeling.[13]

• Design: In vitro receptor‑binding, internalization assays, serum stability tests, and in vivo biodistribution/imaging in mouse tumor models.[13]
• Findings: DOTA‑KP‑10 retained KISS1R binding and internalization, enabling tumor imaging; lutetium‑177 conjugates were proposed for targeted radionuclide therapy.[13]
• Status: Preclinical only; no human efficacy data.[13]

Osteoarthritis and chondrocyte senescence

A 2024 preclinical study evaluated KP‑10 in TNF‑α–induced chondrocyte senescence, a key feature of osteoarthritis.[5]

• Model: Primary murine chondrocytes and ATDC5 cells treated with TNF‑α ± KP‑10.[5]
• Dosing (in vitro): KP‑10 at 50 and 100 nmol/L.[5]
• Sample size: Experiments performed in triplicate cultures across at least three independent repeats (per methods).[5]
• Outcomes: KP‑10 reduced senescence‑associated β‑galactosidase staining, increased telomerase activity, and modulated expression of hTERT and TERF2.[5] It restored SIRT1 expression and suppressed the p53/p21 pathway; SIRT1 knockdown abolished KP‑10’s protective effects.[5]
• Implication: KP‑10 may mitigate chondrocyte senescence via SIRT1–p53/p21 signaling, suggesting potential disease‑modifying relevance in osteoarthritis, though this remains preclinical.[5]

Gestational diabetes mellitus (GDM)

Zhu et al. (2025) examined KP‑10 in a rat model of gestational diabetes.[2]

• Model: Streptozotocin‑induced GDM rats, with additional in vitro work in placental trophoblast cells.[2]
• Sample size: Rats were allocated into control and treatment groups (n≈8–12 per group, as detailed in the article).[2]
• Dosing (in vivo): KP‑10 administered at defined microgram‑per‑kg doses (exact schedule and route detailed in the study), over the gestation period.[2]
• Outcomes: KP‑10 improved glucose tolerance, reduced insulin resistance indices, and modulated trophoblast insulin signaling.[2] Mechanistically, KP‑10 activated the cAMP/PKA pathway, improving insulin sensitivity in trophoblast cells.[2]
• Implication: KP‑10 may influence placental metabolic signaling; clinical relevance in human GDM is unknown.

Toxic injury models

An experimental histopathological study assessed KP‑10 against cadmium chloride–induced toxicity in rats.[3]

• Design: Rats exposed to cadmium chloride with or without KP‑10 co‑administration.[3]
• Dose: KP‑10 given at 20 or 40 nM per animal (regimen defined by the authors).[3]
• Outcomes: KP‑10 reduced histopathological damage in liver, spleen, and kidney compared with cadmium alone.[3]
• Limitations: Small sample size, limited functional endpoints, and non‑standard systemic dosing units.[3]

Skin and anti‑aging research

A study by Seo et al. synthesized KP‑10 and related fragments to assess anti‑aging effects in skin models.[14][15]

• Model: Human dermal fibroblasts and ex vivo or reconstructed skin models.[14][15]
• Findings: KP‑10‑like fragments modulated collagen and matrix metalloproteinase expression and reduced UV‑induced damage markers, suggesting potential cosmeceutical applications.[14][15]
• Status: Preclinical and cosmetic; not developed as a systemic therapeutic.[14][15]

Clinical evidence

Most interventional human data in the kisspeptin field involve other kisspeptin analogues (e.g., kisspeptin‑54) used acutely to stimulate LH/FSH and assess reproductive axis integrity, rather than KP‑10 itself.[12] The available literature does not describe large, controlled therapeutic trials of KP‑10 in any indication as of current reports.[12]

Clinical and research uses

Investigational therapeutic concepts

Based on preclinical work and broader kisspeptin biology, KP‑10 has been explored as a candidate or mechanistic probe in:

• Oncology: As an anti‑metastatic and anti‑angiogenic peptide, and as a vector for radiolabeled imaging/therapy via DOTA‑KP‑10 constructs targeting KISS1R‑positive tumors.[11][13]
• Reproductive and metabolic disorders: As a tool to interrogate GnRH neuronal responsiveness and as a conceptual therapeutic target for conditions such as hypogonadotropic hypogonadism, polycystic ovary syndrome, obesity, and GDM, although other kisspeptin analogues have been more frequently used in humans.[2][12]
• Osteoarthritis: As a senescence‑modulating agent to preserve chondrocyte function.[5]
• Toxicology and organ protection: As an experimental protective agent against heavy metal–induced organ damage in rats.[3]
• Dermatology/cosmeceuticals: As a template for anti‑aging peptide ingredients, typically in topical formulations.[14][15]

Current clinical use

There is no approved medical use of KP‑10 as a therapeutic in humans in the US or EU. Applications remain confined to:

• Laboratory reagent for receptor and signaling studies.
• Preclinical therapeutic candidate, including radiopharmaceutical derivatives.[13]

Any human administration of KP‑10 or structurally close analogues is investigational and typically conducted under clinical trial protocols.

Dosing context

KP‑10 dosing reported in the scientific literature varies widely by model and route. These regimens are experimental and not established for clinical practice.

• In vitro studies: KP‑10 is commonly used at 10–100 nmol/L, with protective or signaling effects documented at 50–100 nM in chondrocyte senescence assays.[5]
• Rodent systemic administration: Preclinical toxicity‑protection and metabolic studies have used nanomolar‑per‑animal or microgram‑per‑kg dosing, administered intraperitoneally or intravenously, across days to weeks of treatment.[2][3] Exact regimens are model‑specific and not standardized.
• Radiopharmaceutical constructs: DOTA‑KP‑10 conjugates for imaging/therapy are dosed according to radioactivity (MBq or mCi) with microgram‑range peptide masses in animal models.[13]

These dosing examples are for contextual understanding of exposure ranges in research and do not constitute therapeutic recommendations.

Safety profile

Preclinical safety signals

• Endothelial and angiogenic effects: KP‑10 inhibits endothelial proliferation and angiogenesis, which may raise concerns about wound healing or placental vascular function if systemically administered at pharmacological levels, although such adverse outcomes have not been systematically characterized.[11]
• Reproductive axis activation: Kisspeptin analogues can acutely increase LH and FSH; excessive or prolonged activation could theoretically lead to ovarian hyperstimulation, menstrual irregularities, or altered sex steroid levels, extrapolated from broader kisspeptin literature.[12]
• Metabolic effects in pregnancy: In GDM rat models, KP‑10 improved insulin sensitivity, but effects on fetal growth, placental function, and long‑term offspring outcomes remain insufficiently studied.[2]
• Organ protection vs toxicity: In cadmium toxicity models, KP‑10 appeared protective rather than harmful at experimental doses; however, histological outcomes alone may not capture all safety aspects.[3]

Human safety

Direct, systematic safety data for KP‑10 itself in humans are limited. Safety information largely comes from short‑term administration of other kisspeptin analogues in small clinical studies, which have generally reported transient flushing, mild nausea, and expected hormonal changes, but these findings cannot be assumed to fully predict KP‑10’s profile.[12]

Comprehensive:

• Cardiovascular, hepatic, renal, and hematologic safety: not adequately defined in humans for KP‑10.
• Genotoxicity, carcinogenicity, reproductive toxicity: no formal regulatory‑grade datasets specific to KP‑10 were identified.

Regulatory status

As of current published information:

• United States (FDA): KP‑10 is not an approved drug. It does not appear in FDA‑approved product lists, and there are no FDA‑approved indications for KP‑10 as a standalone therapeutic or as part of a fixed combination. Radiolabeled DOTA‑KP‑10 constructs are at a pre‑IND/preclinical stage with no marketing authorization.[13]
• European Union (EMA and national agencies): There is no EMA‑authorized medicinal product containing KP‑10. KP‑10 remains an investigational research peptide and radiopharmaceutical scaffold.[13]
• Clinical trials: Registered trials in the kisspeptin field predominantly involve other kisspeptin forms (e.g., kisspeptin‑54) and not KP‑10 as a primary therapeutic agent.[12] KP‑10 is more often used as a mechanistic tool in early‑phase or non‑interventional studies.

Accordingly, KP‑10 should be regarded as an experimental hypothalamic peptide with promising mechanistic and preclinical data in oncology, reproduction, metabolism, and tissue senescence, but without established therapeutic use or regulatory approval in major jurisdictions.